Galaxy Therapeutics Achieves Enrollment Milestone in Critical SEAL IT IDE Trial Galaxy Therapeutics has successfully completed enrollment in its pivotal SEAL IT IDE trial, advancing neurointervention research for brain aneurysms.

Galaxy Therapeutics Achieves Enrollment Milestone in Critical SEAL IT IDE Trial #United_States #Milpitas #Galaxy_Therapeutics #brain_aneurysms #SEAL_IT

Galaxy Therapeutics Unveils State-of-the-Art Manufacturing Facility for Global Expansion Galaxy Therapeutics has inaugurated a new manufacturing facility in Milpitas to enhance its production capabilities and global market outreach for brain aneurysm treatment.

Galaxy Therapeutics Unveils State-of-the-Art Manufacturing Facility for Global Expansion #United_States #Milpitas #Galaxy_Therapeutics #brain_aneurysms

Galaxy Therapeutics Announces Completion of Primary Cohort Enrollment in SEAL IT IDE Trial Galaxy Therapeutics has successfully finished enrolling patients for the primary cohort of its pivotal SEAL IT IDE trial, marking significant progress in treating brain aneurysms.

Galaxy Therapeutics Announces Completion of Primary Cohort Enrollment in SEAL IT IDE Trial #United_States #Milpitas #Galaxy_Therapeutics #SEAL_device #brain_aneurysms